The American Society of Hematology sent their update today which was
focussing on lymphomas and lymphoid neoplasia. Admittedly much of it was rather
too highbrow for me, but it was relevant to me. Bearing in mind the tripe I
read yesterday, the IBMS could learn a lot from The American Society of
|Evaluating Selinexor in Patients With Relapsed/Refractory DLBCL|
Oral selinexor demonstrated durable activity and a 28% response rate in patients with previously treated relapsed and refractory diffuse large B-cell lymphoma.
Bispecific Immune Cell Engager AFM13 Plus Pembrolizumab Produces High Responses in Heavily Treated Hodgkin Lymphoma
Results from a phase Ib study published in Blood suggest that the combination of AFM13 with pembrolizumab may be more effective than either agent alone in patients with heavily treated Hodgkin lymphoma.
First CAR T-Cell Treatment Approved for Mantle Cell Lymphoma
The FDA granted accelerated approval to brexucabtagene autoleucel (formerly KTE-X19), a chimeric antigen receptor T-cell therapy for the treatment of adult patients with relapsed or refractory mantle cell lymphoma.